vida: extract claims from 2026-04-23-who-glp1-obesity-guideline-december-2025

- Source: inbox/queue/2026-04-23-who-glp1-obesity-guideline-december-2025.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md

@@ -60,3 +60,10 @@ ICER's white paper explicitly focuses on 'payer sustainability strategies' rathe
 **Source:** ITIF August 2025, cross-referenced with ICER/KFF data
 
 ITIF's 74 million eligible obesity treatment population figure provides the denominator for the 23% access rate documented in KFF polling. The contrast between ITIF's expansive potential framing (133M users, 0.4% GDP impact) and ICER's payer-crisis framing (>10x PMPM cost increase, $300M BCBS loss) represents the same drug viewed from opposite ends of the access gap—population health potential versus payer fiscal reality.
+
+
+## Supporting Evidence
+
+**Source:** WHO Global Guideline on GLP-1 Medicines for Obesity Treatment, December 2025
+
+WHO explicitly states that current global access and affordability for GLP-1s are 'far below population needs' and that GLP-1s 'should be incorporated into universal health coverage and primary care benefit packages' but acknowledges this is not yet reality anywhere in the developing world. The conditional recommendation status is driven in part by 'potential equity implications,' providing international regulatory confirmation of the structural access inversion.

domains/health/who-glp1-behavioral-supplement-low-certainty-evidence.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: The December 2025 WHO guideline states intensive behavioral interventions may be offered to adults taking GLP-1s for obesity but classifies this as low-certainty evidence
+confidence: experimental
+source: WHO Global Guideline on GLP-1 Medicines for Obesity Treatment, December 2025
+created: 2026-04-23
+title: WHO's GLP-1 guideline rates behavioral interventions as optional supplements with only low-certainty evidence that they enhance pharmacological outcomes
+agent: vida
+sourced_from: health/2026-04-23-who-glp1-obesity-guideline-december-2025.md
+scope: causal
+sourcer: World Health Organization
+related: ["comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "digital-behavioral-support-enables-glp1-dose-reduction-while-maintaining-clinical-outcomes", "who-endorses-glp1-obesity-while-uspstf-maintains-2018-exclusion-creating-international-us-coverage-mandate-gap", "uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation"]
+---
+
+# WHO's GLP-1 guideline rates behavioral interventions as optional supplements with only low-certainty evidence that they enhance pharmacological outcomes
+
+WHO's December 2025 GLP-1 guideline includes a secondary recommendation that intensive behavioral interventions (structured healthy diet + physical activity + professional support) 'may be offered' to adults taking GLP-1s for obesity. Critically, this recommendation is based on 'low-certainty evidence' that behavioral interventions may enhance outcomes. This is notable because it represents the most authoritative global health body's assessment that the evidence base for behavioral programs specifically augmenting GLP-1 pharmacological treatment is weak. The framing is drug-forward: GLP-1 as primary treatment with behavioral as optional supplement, rather than the US approach that requires 'intensive multicomponent behavioral intervention' as primary with drugs as adjunct. The low-certainty qualifier means WHO found insufficient evidence that behavioral programs reliably boost GLP-1 outcomes, despite the widespread clinical assumption that they do. This doesn't challenge the broader claim that behavioral context matters for population-level outcomes, but it adds important nuance: the evidence that behavioral programs specifically enhance pharmacological treatment is weaker than commonly assumed.

domains/health/who-glp1-conditional-endorsement-signals-system-readiness-gap.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: The conditional recommendation is driven by limited long-term data, current costs, inadequate health-system preparedness globally, and potential equity implications
+confidence: experimental
+source: WHO Global Guideline on GLP-1 Medicines for Obesity Treatment, December 2025
+created: 2026-04-23
+title: WHO's December 2025 GLP-1 guideline marks the first global endorsement of pharmacological obesity treatment but its conditional status signals inadequate health system readiness and unresolved equity concerns
+agent: vida
+sourced_from: health/2026-04-23-who-glp1-obesity-guideline-december-2025.md
+scope: structural
+sourcer: World Health Organization
+supports: ["glp-1-access-structure-inverts-need-creating-equity-paradox", "glp-1-receptor-agonists-are-the-largest-therapeutic-category-launch-in-pharmaceutical-history-but-their-chronic-use-model-makes-the-net-cost-impact-inflationary-through-2035"]
+related: ["glp-1-access-structure-inverts-need-creating-equity-paradox", "glp-1-receptor-agonists-are-the-largest-therapeutic-category-launch-in-pharmaceutical-history-but-their-chronic-use-model-makes-the-net-cost-impact-inflationary-through-2035", "federal-glp1-expansion-programs-reproduce-access-hierarchy-at-design-level", "who-endorses-glp1-obesity-while-uspstf-maintains-2018-exclusion-creating-international-us-coverage-mandate-gap", "uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant", "acc-2025-distinguishes-glp1-symptom-improvement-from-mortality-reduction-in-hfpef", "glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation"]
+---
+
+# WHO's December 2025 GLP-1 guideline marks the first global endorsement of pharmacological obesity treatment but its conditional status signals inadequate health system readiness and unresolved equity concerns
+
+On December 1, 2025, WHO issued its first-ever global guideline on GLP-1 medicines for obesity treatment, covering liraglutide, semaglutide, and tirzepatide. Critically, the recommendation is conditional rather than strong. WHO explicitly states the conditional status is driven by: (1) limited data on long-term efficacy and safety, particularly around maintenance and discontinuation; (2) current costs of these medications; (3) inadequate health-system preparedness globally; and (4) potential equity implications. WHO acknowledges that current global access and affordability are 'far below population needs.' This represents a landmark regulatory event—the first time the global health authority has officially endorsed GLP-1 pharmacological treatment for obesity (not just T2DM)—but the conditional framing signals that the evidence base and delivery infrastructure are not yet mature enough for blanket endorsement. The guideline recommends GLP-1s 'may be used' as long-term treatment (continuous use for at least 6 months) based on moderate-certainty evidence, and states they 'should be incorporated into universal health coverage and primary care benefit packages'—but this is not yet reality anywhere in the developing world. The conditional status creates a regulatory signal about evidence maturity and system readiness that differs from a strong endorsement.

inbox/archive/health/2026-04-23-who-glp1-obesity-guideline-december-2025.md

@@ -7,9 +7,12 @@ date: 2025-12-01
 domain: health
 secondary_domains: []
 format: guideline
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-23
 priority: high
 tags: [glp-1, who, obesity, global-guideline, essential-medicines, access, equity, regulatory]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content